Efficacy of S‐1 in second‐line chemotherapy after nab‐paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Issue 2 (28th August 2019)

• Record Type: Journal Article
• Authors: Iede, Kiyotsugu; Yamada, Terumasa; Kato, Ryo; Ueda, Masami; Tsuda, Yujiro; Nakashima, Shinsuke; Ohta, Katsuya; Matsuyama, Jin; Ikenaga, Masakazu; Tominaga, Shusei
• Is Part Of: Cancer reports. Volume 3:Issue 2(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-08-28
• Subjects: chemotherapy -- gemcitabine -- nab‐paclitaxel -- pancreatic cancer -- S‐1; Cancer -- Periodicals; 616.994005
• DOI: 10.1002/cnr2.1215
• Languages: English
• ISSNs: 2573-8348

Abstract

Abstract: Background: Second‐line (2 L) chemotherapy is important for improved survival. However, the efficacy of S‐1 after nab‐paclitaxel plus gemcitabine (AG) for advanced pancreatic cancer (APC) remains unclear. Aim: We retrospectively investigated the clinical impact of S‐1 after AG. Methods and results: From January 2015 to July 2018, 37 patients with APC underwent AG as first‐line chemotherapy at our institute. Of these patients, 14 (38%) underwent S‐1 as 2 L chemotherapy after AG (S‐1 group), five (14%) received another agent after AG, and 18 (49%) underwent no 2 L chemotherapy (best supportive care [BSC] group). The clinical features were retrospectively compared between the S‐1 and BSC groups. Prognostic factors for residual survival (RS) were analyzed using a Cox proportional hazards model. The induction rate of 2 L chemotherapy was 51%, and most patients received S‐1 monotherapy (74%). The disease control rate and progression‐free survival duration were 57.1% and 2.8 months, respectively. The median RS duration in the S‐1 and BSC groups was 5.2 and 2.4 months, respectively; this difference was statistically significant (hazard ratio, 0.33; P = .005). The median overall survival duration in the S‐1 and BSC groups was 12.3 and 5.0 months, respectively; this difference was also statistically significant (hazard ratio, 0.26; P = .001). The efficacy of S‐1 in 2L chemotherapy for RS was identified in the multivariate analysis, as was age (<65 vs ≥65 y) and the presence of liver metastasis. Conclusion: The antitumor activity of S‐1 was retained after AG, and the induction of S‐1 after AG might improve the prognosis of patients with APC.